Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis

Ja Kyung Kim, Soo Jeong Kim, Yuri Kim, Yong Eun Chung, Young Nyun Park, Hyun Ok Kim, Jin Seok Kim, Mi Suk Park, Isao Sakaida, Do Young Kim, Jung Il Lee, Sang Hoon Ahn, Kwan Sik Lee, Kwang Hyub Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decompensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cirrhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of albumin and Child-Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after ABMI, five patients (26.3%) maintained CP class A without LT or death, and five patients (26.3%) had undergone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3%), and lymphoma and colon cancer occurred in one patient each. Three patients (15.8%) were lost to follow-up at months 22, 31, and 33, respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While improved liver function was maintained in some patients for more than 5 years after ABMI, other patients developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.

Original languageEnglish
Pages (from-to)1059-1066
Number of pages8
JournalCell transplantation
Volume26
Issue number6
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Bone Marrow Cells
Liver Cirrhosis
Liver
Bone
Cells
Liver Transplantation
Hepatocellular Carcinoma
Collagen
Lost to Follow-Up
Cell- and Tissue-Based Therapy
Serum Albumin
Colonic Neoplasms
Cause of Death
Veins
Lymphoma
Fibrosis
Bone Marrow
Clinical Trials
Processing
Survival

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Kim, Ja Kyung ; Kim, Soo Jeong ; Kim, Yuri ; Chung, Yong Eun ; Park, Young Nyun ; Kim, Hyun Ok ; Kim, Jin Seok ; Park, Mi Suk ; Sakaida, Isao ; Kim, Do Young ; Lee, Jung Il ; Ahn, Sang Hoon ; Lee, Kwan Sik ; Han, Kwang Hyub. / Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis. In: Cell transplantation. 2017 ; Vol. 26, No. 6. pp. 1059-1066.
@article{2a7ea314d7664dcbb3fb4e32789f70e6,
title = "Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis",
abstract = "Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decompensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cirrhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of albumin and Child-Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after ABMI, five patients (26.3{\%}) maintained CP class A without LT or death, and five patients (26.3{\%}) had undergone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3{\%}), and lymphoma and colon cancer occurred in one patient each. Three patients (15.8{\%}) were lost to follow-up at months 22, 31, and 33, respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While improved liver function was maintained in some patients for more than 5 years after ABMI, other patients developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.",
author = "Kim, {Ja Kyung} and Kim, {Soo Jeong} and Yuri Kim and Chung, {Yong Eun} and Park, {Young Nyun} and Kim, {Hyun Ok} and Kim, {Jin Seok} and Park, {Mi Suk} and Isao Sakaida and Kim, {Do Young} and Lee, {Jung Il} and Ahn, {Sang Hoon} and Lee, {Kwan Sik} and Han, {Kwang Hyub}",
year = "2017",
month = "1",
day = "1",
doi = "10.3727/096368917X694778",
language = "English",
volume = "26",
pages = "1059--1066",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "6",

}

Kim, JK, Kim, SJ, Kim, Y, Chung, YE, Park, YN, Kim, HO, Kim, JS, Park, MS, Sakaida, I, Kim, DY, Lee, JI, Ahn, SH, Lee, KS & Han, KH 2017, 'Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis', Cell transplantation, vol. 26, no. 6, pp. 1059-1066. https://doi.org/10.3727/096368917X694778

Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis. / Kim, Ja Kyung; Kim, Soo Jeong; Kim, Yuri; Chung, Yong Eun; Park, Young Nyun; Kim, Hyun Ok; Kim, Jin Seok; Park, Mi Suk; Sakaida, Isao; Kim, Do Young; Lee, Jung Il; Ahn, Sang Hoon; Lee, Kwan Sik; Han, Kwang Hyub.

In: Cell transplantation, Vol. 26, No. 6, 01.01.2017, p. 1059-1066.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis

AU - Kim, Ja Kyung

AU - Kim, Soo Jeong

AU - Kim, Yuri

AU - Chung, Yong Eun

AU - Park, Young Nyun

AU - Kim, Hyun Ok

AU - Kim, Jin Seok

AU - Park, Mi Suk

AU - Sakaida, Isao

AU - Kim, Do Young

AU - Lee, Jung Il

AU - Ahn, Sang Hoon

AU - Lee, Kwan Sik

AU - Han, Kwang Hyub

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decompensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cirrhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of albumin and Child-Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after ABMI, five patients (26.3%) maintained CP class A without LT or death, and five patients (26.3%) had undergone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3%), and lymphoma and colon cancer occurred in one patient each. Three patients (15.8%) were lost to follow-up at months 22, 31, and 33, respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While improved liver function was maintained in some patients for more than 5 years after ABMI, other patients developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.

AB - Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decompensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cirrhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of albumin and Child-Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after ABMI, five patients (26.3%) maintained CP class A without LT or death, and five patients (26.3%) had undergone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3%), and lymphoma and colon cancer occurred in one patient each. Three patients (15.8%) were lost to follow-up at months 22, 31, and 33, respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While improved liver function was maintained in some patients for more than 5 years after ABMI, other patients developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85020659899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020659899&partnerID=8YFLogxK

U2 - 10.3727/096368917X694778

DO - 10.3727/096368917X694778

M3 - Article

C2 - 28120743

AN - SCOPUS:85020659899

VL - 26

SP - 1059

EP - 1066

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 6

ER -